pyridoclax

04/01/2019 - "Pyridoclax is an original lead, recently identified as very promising in treatment of chemoresistant cancers. "
01/15/2017 - "Pyridoclax is an original oligopyridine lead, very promising in treatment of chemoresistant cancers. "
09/25/2020 - "In addition, anti-tumor effects of the Pyridoclax-loaded nanoemulsions (PNEs) showed a 2.5-fold higher activity on chemoresistant ovarian cancer cells than free Pyridoclax. "
01/01/2020 - "Pyridoclax is considered a promising anticancer drug, acting as a protein-protein interaction disruptor, with potential applications in the treatment of ovarian, lung, and mesothelioma cancers. "
02/26/2015 - "Without cytotoxic activity when administered as a single agent, pyridoclax induced apoptosis in combination with Bcl-xL-targeting siRNA or with ABT-737 in ovarian, lung, and mesothelioma cancer cells. "

09/25/2020 - "Pyridoclax is an original lead, recently identified as very promising in treatment of chemoresistant ovarian cancers. "
09/25/2020 - "Pyridoclax-loaded nanoemulsion for enhanced anticancer effect on ovarian cancer."
09/01/2020 - "Pyridoclax, a promising BH3 mimetic inhibitor, interacts directly with Mcl-1 and induces massive apoptosis at a concentration of 15 µM in combination with anti-Bcl-xL strategies in chemo-resistant ovarian cancer cell lines. "
09/25/2020 - "In addition, anti-tumor effects of the Pyridoclax-loaded nanoemulsions (PNEs) showed a 2.5-fold higher activity on chemoresistant ovarian cancer cells than free Pyridoclax. "

01/01/2020 - "Pyridoclax is considered a promising anticancer drug, acting as a protein-protein interaction disruptor, with potential applications in the treatment of ovarian, lung, and mesothelioma cancers. "
02/26/2015 - "Without cytotoxic activity when administered as a single agent, pyridoclax induced apoptosis in combination with Bcl-xL-targeting siRNA or with ABT-737 in ovarian, lung, and mesothelioma cancer cells. "